<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091723</url>
  </required_header>
  <id_info>
    <org_study_id>0196</org_study_id>
    <nct_id>NCT05091723</nct_id>
  </id_info>
  <brief_title>TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation</brief_title>
  <official_title>Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of Inhaled Nezulcitinib (TD-0903) Administered in the Setting of Supplemental Oxygenation Scenarios in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma&#xD;
      pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903)&#xD;
      with supplemental oxygenation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, open-label, fixed-sequence, 4-period study to evaluate the plasma PK, safety and&#xD;
      tolerability of single inhaled doses of nezulcitinib (TD-0903) administered under different&#xD;
      supplemental oxygenation scenarios in healthy participants.&#xD;
&#xD;
      Approximately 14 healthy adult male and female participants will receive a single inhaled&#xD;
      dose of nezulcitinib using a nebulizer device on Day 1 of each administration period, under&#xD;
      different supplementary oxygenations conditions.&#xD;
&#xD;
      Administration A: Dose A nezulcitinib delivered by nasal inhalation via the Aerogen Solo with&#xD;
      a high-flow nasal cannula circuit delivering supplemental oxygen, Administration B: Dose A&#xD;
      nezulcitinib delivered by oral inhalation via the Aerogen Solo together with the Aerogen&#xD;
      Ultra handheld device with a low-flow nasal cannula delivering supplemental oxygen,&#xD;
      Administration C: Dose A nezulcitinib delivered by oral inhalation via the Aerogen Solo&#xD;
      together with the Aerogen Ultra handheld device with a high-flow nasal cannula delivering&#xD;
      supplemental oxygen, Administration D: Nezulcitinib delivered by inhalation. Route to be&#xD;
      determined based on data from administration A-C.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Predose and at prespecified time points up to 48 hours after dosing on Day 1 of each period</time_frame>
    <description>The area under the concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of TD-0903</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Predose and at prespecified time points up to 48 hours after dosing on Day 1 of each period</time_frame>
    <description>The area under the concentration time curve, from time 0 to the last observed non-zero concentration (AUC0-t) of TD-0903</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Predose and at prespecified time points up to 48 hours after dosing on Day 1 of each period</time_frame>
    <description>Maximum observed concentration (Cmax) of TD-0903 in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 through 7 following dosing on Day 1 in each of 4 Periods</time_frame>
    <description>Number and severity of treatment emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Administration Scenario A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TD-0903 at Dose A on Day 1, Period 1 delivered by nasal inhalation via nebulizer device with a high-flow nasal cannula delivering supplemental oxygen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration Scenario B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TD-0903 at Dose A on Day 1, Period 2 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via low-flow nasal cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration Scenario C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TD-0903 at Dose A on Day 1, Period 3 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via high-flow nasal cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration Scenario D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TD-0903 at Dose B on Day 1, Period 4 delivered by a route to-be-determined based on data from Scenarios A, B and C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nezulcitinib (TD-0903) Dose A</intervention_name>
    <description>TD-0903 Dose A</description>
    <arm_group_label>Administration Scenario A</arm_group_label>
    <arm_group_label>Administration Scenario B</arm_group_label>
    <arm_group_label>Administration Scenario C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nezulcitinib (TD-0903) Dose B</intervention_name>
    <description>TD-0903 Dose B</description>
    <arm_group_label>Administration Scenario D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 and ≤ 35.0 kg/m2 and weighs at least 50 kg at screening&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history, physical&#xD;
             examination, spirometry, laboratory profiles, vital signs or ECGs&#xD;
&#xD;
          -  Forced expiratory volume of 1 second (FEV1) ≥80% predicted at screening and prior to&#xD;
             dosing&#xD;
&#xD;
          -  No clinically significant abnormalities in the results of laboratory&#xD;
&#xD;
          -  Female subjects must be either of non-childbearing potential or if of childbearing&#xD;
             potential, subject must not be pregnant or breastfeeding, and must agree to use a&#xD;
             highly effective birth control method&#xD;
&#xD;
          -  Male subjects must agree to use condoms to prevent potential fetal or partner exposure&#xD;
             through seminal fluid, in addition to the use of highly effective pregnancy prevention&#xD;
             measures with female partners of childbearing potential&#xD;
&#xD;
          -  Able to understand the correct technique for the use of the nebulizer device&#xD;
&#xD;
          -  Other inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant medical or psychiatric condition&#xD;
&#xD;
          -  Abnormal ECG measurements at screening&#xD;
&#xD;
          -  Any signs of respiratory tract infection within 6 weeks of screening&#xD;
&#xD;
          -  Has a current bacterial, parasitic, fungal, or viral infection; any infection&#xD;
             requiring hospitalization or intravenous antibiotics within 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Has any condition of the oro-laryngeal or respiratory tract&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse&#xD;
&#xD;
          -  Positive urine drugs of abuse test&#xD;
&#xD;
          -  Positive urine or breath alcohol results&#xD;
&#xD;
          -  Uses or has used tobacco or nicotine-containing products (e.g., cigarettes, cigars,&#xD;
             chewing tobacco, snuff, patches etc.) within 6 months prior to screening&#xD;
&#xD;
          -  Tests positive for active COVID-19&#xD;
&#xD;
          -  Additional exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>1-855-633-8479</phone>
    <email>medinfo@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute lung injury</keyword>
  <keyword>ALI</keyword>
  <keyword>Coronavirus Disease-2019</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Supplemental oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

